JPWO2021050217A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021050217A5 JPWO2021050217A5 JP2022516046A JP2022516046A JPWO2021050217A5 JP WO2021050217 A5 JPWO2021050217 A5 JP WO2021050217A5 JP 2022516046 A JP2022516046 A JP 2022516046A JP 2022516046 A JP2022516046 A JP 2022516046A JP WO2021050217 A5 JPWO2021050217 A5 JP WO2021050217A5
- Authority
- JP
- Japan
- Prior art keywords
- spik
- seq
- sequence
- amino acids
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 238000002405 diagnostic procedure Methods 0.000 claims 5
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 101100108506 Arabidopsis thaliana AKT6 gene Proteins 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102220080600 rs797046116 Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025159797A JP2026012693A (ja) | 2019-09-11 | 2025-09-26 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899024P | 2019-09-11 | 2019-09-11 | |
| US62/899,024 | 2019-09-11 | ||
| PCT/US2020/046782 WO2021050217A1 (en) | 2019-09-11 | 2020-08-18 | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159797A Division JP2026012693A (ja) | 2019-09-11 | 2025-09-26 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547574A JP2022547574A (ja) | 2022-11-14 |
| JPWO2021050217A5 true JPWO2021050217A5 (https=) | 2023-09-04 |
| JP2022547574A5 JP2022547574A5 (https=) | 2023-09-04 |
Family
ID=72243286
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516046A Pending JP2022547574A (ja) | 2019-09-11 | 2020-08-18 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
| JP2025159797A Pending JP2026012693A (ja) | 2019-09-11 | 2025-09-26 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025159797A Pending JP2026012693A (ja) | 2019-09-11 | 2025-09-26 | 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240043512A1 (https=) |
| EP (1) | EP4028132A1 (https=) |
| JP (2) | JP2022547574A (https=) |
| KR (1) | KR20220080098A (https=) |
| CN (1) | CN114901699A (https=) |
| CA (1) | CA3150538A1 (https=) |
| WO (1) | WO2021050217A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3996816A1 (en) * | 2019-07-08 | 2022-05-18 | Imcare Biotech, LLC | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| KR100332254B1 (ko) | 1993-10-01 | 2002-09-27 | 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 | 신규인펩티드유도체 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| CA2703140A1 (en) * | 2007-10-25 | 2009-04-30 | Viventia Biotech Inc. | Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
| MX2011010265A (es) | 2009-04-01 | 2011-10-11 | Genentech Inc | Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso. |
| US20140308657A1 (en) * | 2010-12-09 | 2014-10-16 | Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine | Serine protease inhibitor kazal antibodies |
| WO2014127200A1 (en) * | 2013-02-15 | 2014-08-21 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| WO2015164757A1 (en) * | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| AU2017239637A1 (en) * | 2016-03-29 | 2018-11-15 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| CN112292401A (zh) | 2018-03-06 | 2021-01-29 | 英凯尔生物科技有限责任公司 | 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 |
| CN109678950B (zh) * | 2019-01-08 | 2022-05-10 | 灏灵赛奥（天津）生物科技有限公司 | spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品 |
| EP3996816A1 (en) * | 2019-07-08 | 2022-05-18 | Imcare Biotech, LLC | Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use |
-
2020
- 2020-08-18 WO PCT/US2020/046782 patent/WO2021050217A1/en not_active Ceased
- 2020-08-18 EP EP20762027.9A patent/EP4028132A1/en active Pending
- 2020-08-18 CN CN202080071514.XA patent/CN114901699A/zh active Pending
- 2020-08-18 US US17/641,780 patent/US20240043512A1/en active Pending
- 2020-08-18 CA CA3150538A patent/CA3150538A1/en active Pending
- 2020-08-18 KR KR1020227011715A patent/KR20220080098A/ko active Pending
- 2020-08-18 JP JP2022516046A patent/JP2022547574A/ja active Pending
-
2025
- 2025-09-26 JP JP2025159797A patent/JP2026012693A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2504551C2 (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| US20210231665A1 (en) | Detection methods employing hcv core lipid and dna binding domain monoclonal antibodies | |
| RU2014102007A (ru) | Методы предсказания, обнаружения и уменьшения неспецифической интерференции белков в способах анализа с использованием одиночных вариабельных доменов иммуноглобулинов | |
| JP2007527406A5 (https=) | ||
| JP2009517057A5 (https=) | ||
| CN107982531A (zh) | 与赖氨酰氧化酶样蛋白2 (loxl2)相关的治疗和诊断方法 | |
| JP2005528914A5 (https=) | ||
| JP2025111457A5 (https=) | ||
| JP2021515597A5 (https=) | ||
| JP2020189843A5 (https=) | ||
| CN114578066B (zh) | 检测β-淀粉样蛋白的产品和方法 | |
| KR102078879B1 (ko) | 돼지파보바이러스에 특이적인 단일클론항체 및 이의 용도 | |
| CN114594272A (zh) | 用于检测β-淀粉样蛋白的产品和方法 | |
| JPWO2021050217A5 (https=) | ||
| KR20230124280A (ko) | 메르스 코로나 바이러스의 뉴클레오캡시드 단백질에 특이적인 진단용 항체 및 이의 용도 | |
| WO2022238481A1 (en) | Antibodies | |
| JPWO2019173503A5 (https=) | ||
| CN118852448B (zh) | 蒜氨酸单克隆抗体及其制备方法与应用 | |
| CN118878691B (zh) | 蒜氨酸单克隆抗体及其制备方法与应用 | |
| CN121378459B (zh) | MHBs的特异性结合蛋白、核酸分子、载体、细胞、检测试剂盒及其制备方法与应用 | |
| JPWO2021007338A5 (https=) | ||
| JPWO2021188851A5 (https=) | ||
| CN121914268A (zh) | 雌二醇的特异性结合抗体及其制备方法与应用 | |
| JP2023156197A5 (https=) | ||
| KR20230157812A (ko) | 항-키티나제-3-유사 단백질 1 항체 |